Intuitive Surgical reported strong 2025 results, including 51% year-over-year growth for its Ion platform and exceeding Q4 forecasts. However, the stock declined due to softer-than-expected 2026 procedure growth guidance for its core da Vinci system. While the company is expanding globally with its new da Vinci 5 platform, concerns exist about pricing sensitivity and adoption hurdles outside the U.S. The market reaction was negative despite the strong recent performance.